Jimmy Khandalavala, MD
Obstetrics & Gynecology · Omaha, NENPI 1558471755
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 27.0% of the total.
Across 77 payments — averaging $24.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$505
- Mayne Pharma Commercial LLC$246
- Sumitomo Pharma America, Inc.$209
- Channel Medsystems, Inc.$123
- Pfizer$117
- Boston Scientific$102
- plus $564 from 19 others
Across 5 payments — averaging $5948.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coloplast$30K
What the payments were for
- Food & beverage$1,83598%
- Education$312%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $505 |
| Mayne Pharma Commercial LLC | 6 | $246 |
| Sumitomo Pharma America, Inc. | 10 | $209 |
| Channel Medsystems, Inc. | 1 | $123 |
| Pfizer | 7 | $117 |
| Boston Scientific | 1 | $102 |
| Astellas Pharma US Inc | 4 | $82 |
| Myriad Women's Health, Inc. | 1 | $71 |
| Myovant Sciences Inc. | 2 | $38 |
| Bayer | 3 | $38 |
| Therapeuticsmd, Inc. | 2 | $35 |
| Mallinckrodt Enterprises LLC | 2 | $33 |
| Covidien LP | 2 | $32 |
| Medtronic | 1 | $30 |
| Asensus Surgical, Inc. | 1 | $29 |
| Dexcom, Inc. | 1 | $29 |
| Medicem Inc. | 1 | $20 |
| Organon | 1 | $19 |
| Caldera Medical, Inc | 1 | $18 |
| Coloplast | 1 | $18 |
| Evofem Biosciences, Inc. | 1 | $18 |
| Agile Therapeutics, Inc. | 1 | $15 |
| Exeltis, USA Inc. | 1 | $14 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
| Hologic Sales And Service, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMPHION$102
How this compares
$1,866 in reported general payments places this provider in the 70th percentile of 242 obstetrics & gynecology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 24 | $16,861 |
| MyfembreeRelugolix/Estradiol/Norethindr | 11 | $15,923 |
| PremarinEstrogens, Conjugated | 20 | $6,883 |
| Estradiol | 65 | $2,074 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 12 | $1,509 |
| Norethindrone Acetate | 14 | $583 |
| ValacyclovirValacyclovir Hcl | 12 | $413 |
| Estradiol (Twice Weekly)Estradiol | 12 | $311 |
| Cephalexin | 25 | $283 |
| Bethanechol Chloride | 13 | $255 |
| Medroxyprogesterone Acetate | 15 | $246 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 12 | $202 |
| Gabapentin | 18 | $119 |
| Metronidazole | 12 | $36 |
| Levothyroxine Sodium | 11 | $28 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $82 | $16,86124 claims |
| Sumitomo Pharma America, Inc.Myfembree | $209 | $15,92311 claims |
| PfizerPremarin | $117 | $6,88320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 242 obstetrics & gynecology providers in Nebraska.
Other obstetrics & gynecology in Omaha
- John CoteOmaha$236K
- Robin ClemmerOmaha$19K
- Susan UlmerOmaha$8K
- Jennifer CeraOmaha$5K
- Trevor WatsonOmaha$5K
- Jamie SeemanOmaha$4K
- Malorie HoweOmaha$4K
- Sonya TranOmaha$3K
- Jessica Prusa FloresOmaha$3K
- Tedette EllisOmaha$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.